Posted as supplied by author

Table B Individual results of unconfounded randomised trials of one antiplatelet regimen versus another†
 


Trial name
Ref
Data
APT1 vs APT2
Average

duration
Patients
Non-fatal MI
Non-fatal stroke
Vasc deaths
Vasc events
Non-vasc deaths
Major bleeds
APT1
APT2
APT1
APT2
APT1
APT2
APT1
APT2
APT1
APT2
APT1
APT2
APT1
APT2
Previous myocardial infarction
PARIS-I
3
I
A972 + D225 vs A972
41m
810
810
55
50
8
7
74
73
135
130
14
12
-
(0)
-
(0)
Acute myocardial infarction
Misra
207
T
A150 + D300 vs S
42d
25
25
0
0
0
0
2
1
2
1
0
0
0
(0)
0
(0)
Hart
208
T
A1500 + D300 vs A1500
12d
44
46
-
-
-
-
0
0
0
0
0
0
-
(0)
-
(0)
Frankfurt
209
T
A1320 + D300 vs A1320
14d
11
14
0
0
0
0
0
1
0
1
0
0
0
(0)
0
(0)
DUCCS-II
210
P
A325 vs A81 (FIB)
5d (7d)
83
79
2
0
0
3
4
1
6
4
0
0
[16]
[11]
TIM
211
I
TF600 vs A300
35d
1135
1140
28
15
6
13
75
81
108
109
3
1
-
(-)
-
(-)
RAPT
212
I
R vs A160 (SK)
14d
452
455
11
17
0
6
29
32
40
55
0
0
3
(2)
0
(1)
Verstraete
213
T
R vs A100 (H + tPA)
60h (72h)
67
23x3
3
1
1
1
6
1
10
3
0
0
2
(0)
0
(0)
IMPACT-AMI
214
P
A325 + IN vs A325 (H + tPA)
24h (7d)
35
13
0
0
2
0
11
0
13
0
0
0
-
(-)
-
(-)
Previous stroke or transient ischaemic attack
Canadian Co-op
31,32
I
S vs A1300
26m
156
144
8
4
29
17
12
11
47
32
5
3
-
(0)
-
(0)
Canadian Co-op
31,32
I
A1300 + S vs A1300
26m
146
144
4
4
12
17
6
11
21
32
4
3
-
(0)
-
(0)
Canadian Co-op
31,32
I
A1300 + S vs S
26m
146
156
4
8
12
29
6
12
21
47
4
5
-
(0)
-
(0)
Toulouse-TIA
33
I
A900 + D150 vs A900
34m
137
147
0
0
1
4
11
7
12
11
5
6
-
(0)
-
(0)
AICLA
34
I
A990 + D225 vs A990
36m
202
198
2
2
16
16
12
13
30
31
5
6
0
(0)
0
(0)
UK-TIA
39
I
A1200 vs A300
50m
815
806
18
21
63
63
89
91
168
174
23
18
4
(2)
5
(0)
TASS
215
T
TC500 vs A1300
42m
1529
1540
83
75
156
189
131
131
370
395
44
67
1
(0)
12
(2)
Japanese-B
216, 217
I
TC200 vs A500
12m
170
170
1
1
7
13
1
2
8
16
0
0
-
(0)
-
(0)
ATIAIS
218
I
S vs A1000
22m
63
64
1
0
2
2
2
1
5
3
0
0
0
(0)
0
(0)
ACCSG
219, 220
I
A1300 + D300 vs A1300
30m
448
442
11
10
38
45
31
31
79
85
15
8
-
(0)
-
(0)
Dutch-TIA
221
I
A283 vs A30
31m
1576
1555
28
36
109
90
107
105
240
228
44
55
30
(9)
23
(5)
Matias-Guiu
222
P
TF900 vs A330
47m
106
111
-
-
-
-
-
-
21
32
-
-
-
(-)
-
(-)
Smirne
223, 224
P
TF600 vs A300
6m
90
93
-
-
6
5
0
0
6
5
0
0
-
(-)
-
(-)
ESPS-2
50, 51
T
D400 vs A50
24m
1654
1649
31
17
145
158
125
118
297
293
63
64
6
(2)
16
(4)
ESPS-2
50, 51
T
A50 + D400 vs A50
24m
1650
1649
11
17
109
158
117
118
235
293
68
64
23
(7)
16
(4)
ESPS-2
50, 51
T
A50 + D400 vs D400
24m
1650
1654
11
31
109
145
117
125
235
297
68
63
23
(7)
6
(2)
Italian-TIA
225
T
ID vs A300
18m
533
533
4
3
27
20
2
2
33
35
4
3
[3]
[6]
JETS-1
226
T
E5510 vs A324
3m
148
79x2
-
-
1
0
0
0
1
1
0
0
0
(0)
0
(0)
JETS-2
227
I
E5510 vs TC200
12m
165
172
2
0
11
6
0
1
13
7
1
1
0
(0)
0
(0)
TISS
228
T
ID vs TC500
12m
811
821
4
1
18
13
25
12
47
26
1
0
0
(0)
0
(0)
Acute stroke
Capildeo
229
T
A900 + D400 vs A900
15d
88
95
0
0
0
0
6
3
6
3
3
2
1
(0)
0
(2)
Unstable angina 
Canadian
61
I
S vs A1300
18m
140
139
6
9
0
1
14
8
20
17
1
1
0
(0)
0
(0)
Canadian
61
I
A1300 + S vs A1300
18m
137
139
9
9
3
1
6
8
17
17
1
1
1
(0)
0
(0)
Canadian
61
I
A1300 + S vs S
18m
137
140
9
6
3
0
6
14
17
20
1
1
1
(0)
0
(0)
ALDUSA-pilot‡
64
I
A325 vs A40
12m
28
28
4
1
0
1
1
0
5
2
0
0
-
(0)
-
(0)
Sadowski
230
T
TC500 vs A50 (H)
3m
154
166
14
24
0
0
5
5
19
29
0
0
2
(0)
0
(0)
Cipollone
231
P
ID vs A320
48h
10
10
0
0
-
-
0
0
0
0
0
0
0
(0)
0
(0)
Norris
232
T
GRB vs A300
31d
31
28
1
1
0
0
1
0
2
1
0
0
0
(0)
0
(0)
Schulman
233
P
IN vs A325 (H)
38h
153
74
1
1
0
0
0
0
1
1
0
0
6
(0)
1
(0)
Canadian-lamifiban
234
P
A325 + L vs A325
84h (1m)
242
123
7
7
0
0
3
5
10
12
0
0
7
(0)
1
(0)
ECSG-UA
235
P
A80 + 7E3 vs A80 (H)
21h (7d)
30
30
1
1
0
0
0
1
1
2
0
0
3
(-)
2
(-)
PARAGON-A
236
P
A + L vs A (H)
72h (30d)
750
758
60
67
6
3
25
22
91
92
0
0
[57]
[36]
PRISM-PLUS
237
T
A + TI vs A (H)
71h (30d)
773
797
39
62
8
4
27
33
74
99
1
3
30
(1)
20
(2)
PURSUIT
238
P
A160-325 + IN vs A160-325 (H)
84h (30d)
4722
4739
506
569
33
38
165
175
704
782
0
0
[548]
[436]
Mattioli-UA1
239
T
PI vs TR
3m
58
62
4
5
3
2
11
12
17
18
0
0
0
(0)
0
(0)
Heart failure
Barzizza
116
T
A 300 + D200 vs A300
6m
26
26
0
0
0
0
1
0
1
0
0
0
0
(0)
0
(0)
Coronary artery bypass 
Sharma
240
T
A975 + D225 vs A975
12m
60
64
-
-
-
-
0
0
0
0
0
0
-
(0)
-
(0)
Wadsworth
79
T
A975 + D225 vs A975
12m
49
47
-
-
0
1
1
1
1
2
0
0
-
(0)
-
(0)
VA Co-op CABG
81
T
A975 vs A325
12m
155
154
10
11
2
2
6
5
18
18
0
1
7
(0)
12
(0)
VA Co-op CABG
81
T
S vs A325, A975
12m
148
309
9
21
0
4
4
11
13
36
0
1
5
(0)
19
(0)
VA Co-op CABG
81
T
A975 + D225 vs S
12m
162
148
10
9
1
0
7
4
18
13
3
0
6
(0)
5
(0)
VA Co-op CABG
81
T
A975 + D225 vs A975
12m
162
155
10
10
1
2
7
6
18
18
3
0
6
(0)
7
(0)
GESIC
83
T
A150 + D225 vs A150
28d
368
373
-
-
-
-
9
13
9
13
0
0
8
(0)
8
(0)
SINBA
241
T
A975 + D225 vs ID
12m
279
290
4
0
0
0
4
1
8
1
1
0
0
(0)
0
(0)
Agnew
242
T
A100 + D300 vs A100
12m
51
52
9
3
2
1
2
2
13
6
0
0
6
(0)
6
(0)
CABADAS
243
I
A50 + D400 vs A50
12m
296
309
28
19
5
1
5
8
38
28
0
0
18
(1)
15
(1)
Guiteras
88
T
D225 + TF900 vs A150 + D225
7m
69
72
1
0
0
0
5
5
6
5
0
0
0
(0)
0
(0)
Leeds-indobufen
244
T
A900 + D225 vs ID
12m
399
404
0
0
0
0
8
9
8
9
4
4
0
(2)
0
(1)
Prague
245
T
A400 + D225 vs ID
12m
100
94
0
1
0
0
1
1
1
2
1
2
-
(0)
-
(0)
Coronary angioplasty
White
246
T
A650 + D225 vs TC500
6m
123
122
5
9
0
0
0
2
5
11
0
0
0
(0)
0
(0)
Mufson
247
T
A1500 vs A80
5m
253
242
9
9
0
0
0
0
9
9
0
0
0
(0)
0
(0)
SIAC
248
T
ID vs A325
6m
161
162
4
3
0
0
0
1
4
4
1
1
0
(0)
0
(0)
Lembo
249
T
A975 + D225 vs A975 (H)
7d
129
139
7
4
0
0
1
0
8
4
0
0
0
(0)
0
(0)
German-aspirin
250
I
A1400 vs A350
5m
101
99
-
-
-
-
2
3
6
5
0
2
-
(-)
-
(-)
M-HEART II
108
P
ST vs A325
6m
249
248
3
2
-
-
0
1
3
3
-
-
-
(-)
-
(-)
STARC
251
T
TR vs A300
6m
198
196
3
2
0
1
0
0
3
3
0
0
0
(0)
0
(0)
Philadelphia
252
P
A325 + D75 vs A325
48h
146
134
1
2
-
-
0
0
1
2
0
0
-
(0)
-
(0)
CAPTURE
253
P
A>=50 + 7E3 vs A>=50 (H)
24h (30d)
630
636
24
49
1
3
6
8
31
60
0
0
[44]
[21]
EPIC
254, 255
P
A325 + 7E3 vs A325 (H)
1d (30d)
1403
696x2
80
60
2
1
21
12
103
73
0
0
[201]
[49]
EPILOG
256
P
A325 + 7E3 vs A325 (H)
12h (30d)
918
939
34
78
0
0
4
7
38
85
0
0
[30]
[37]
Harrington
257
P
A325 + IN vs A325 (H)
20h (7d)
54
19x3
1
2
0
0
0
0
1
2
0
0
2
(0)
0
(0)
IMPACT-I
258
P
A325 + IN vs A325 (H)
1d (30d)
101
49x2
2
1
0
0
1
1
3
2
0
0
8
(0)
3
(0)
IMPACT-II
259
P
A325 + IN vs A325 (H)
1d (30d)
2682
1,328x2
172
97
16
8
18
15
206
120
-
-
[153]
[69]
Kereiakes
260
P
A325 + TI vs A325 (H)
1d (7d)
73
20x4
0
0
0
0
0
0
0
0
0
0
1
(0)
1
(0)
RESTORE
261
T
A325 + TI vs A325 (H)
36h (30d)
1108
1104
45
60
5
3
8
7
58
70
1
1
55
(1)
37
(1)
Simpfendorfer
262
P
A160 + X vs A160
30d
20
10x2
-
-
-
-
1
0
1
0
0
0
1
(1)
0
(0)
Take
263
P
CL vs APT
5m
35
33
0
0
-
-
-
-
0
0
-
-
0
(0)
0
(0)
Percutaneous coronary stenting
Hara
264
T
CL vs A243
6m
18
17
0
0
0
0
0
0
0
0
0
0
0
(0)
0
(0)
STARS
265
T
A325 + TC500 vs A325
30d
546
557
26
31
0
2
0
1
26
33
0
0
15
(0)
7
(1)
Intermittent claudication
Hess
135
T
A990 + D225 vs A990
24m
80
80
0
2
0
0
2
1
2
3
1
1
0
(0)
0
(0)
Libretti
266
T
A600 + D225 vs A600
6m
27
27
1
1
0
0
1
2
2
3
0
0
0
(0)
0
(0)
Schoop-I
141, 142, 143
T
A990 + D225 vs A990
60m
100
100
1
3
1
1
6
2
8
6
2
0
3
(0)
0
(0)
Schoop-II
267
T
TC500 vs A1500
24m
31
31
0
0
0
0
0
3
0
3
0
2
0
(0)
0
(0)
Giansante
268
I
A500 + D225 vs TC500
6m
100
100
0
0
0
0
0
0
0
0
0
0
0
(0)
0
(0)
Peripheral grafts 
Rochester
162
T
A975 + D225 vs A975
12m
16
16
0
0
1
0
2
0
3
0
0
0
0
(0)
1
(0)
Bollinger
269
T
A1000 + D225 vs A1000
24m
41
40
3
0
1
0
2
0
6
0
1
2
0
(0)
0
(0)
Harjola
172
T
D450 vs A1500
10d
100
100
0
0
0
0
0
0
0
0
0
0
0
(0)
0
(0)
Harjola
172
T
A1500 + D450 vs A1500
10d
100
100
0
0
0
0
0
0
0
0
0
0
0
(0)
0
(0)
Harjola
172
T
A1500 + D450 vs D450
10d
100
100
0
0
0
0
0
0
0
0
0
0
0
(0)
0
(0)
Bologna-II
270
T
A900 + D225 vs ID
12m
57
56
-
-
-
-
2
0
2
0
-
-
2
(-)
0
(-)
Peripheral angioplasty
Heiss
174
T
A990 vs A300 (D)
6m
66
66
0
3
0
1
1
0
1
4
0
0
0
(0)
0
(0)
Hess-PTA
271
T
A990 + D225 vs A990
14d
55
55
0
0
0
0
0
0
0
0
0
0
0
(0)
0
(0)
ARPA
272
I
A1000 vs A300
6m
111
113
1
0
0
0
1
1
2
1
1
0
0
(0)
0
(0)
Minar
273
I
A1000 vs A100
24m
107
109
7
6
2
1
14
13
23
20
0
0
1
(0)
0
(0)
LARA
274
T
A900 vs A50
12m
191
192
2
3
4
1
3
0
9
4
3
2
1
(0)
0
(0)
Haemodialysis
Albert
275
T
S vs A1500
42d
19
17
0
0
0
0
0
0
0
0
0
0
0
(0)
2
(0)
Heidelberg-B
276
T
TC500 vs A500
35d
10
10
-
-
-
-
-
-
-
-
-
-
-
(-)
-
(-)
Sreedhara
189
T
D225 vs A325
18m
29
26
0
0
0
0
1
0
1
0
0
1
5
(0)
4
(0)
Sreedhara
189
T
A325 + D225 vs A325
18m
29
26
1
0
0
0
0
0
1
0
2
1
4
(0)
4
(0)
Sreedhara
189
T
A325 + D225 vs D225
18m
29
29
1
0
0
0
0
1
1
1
2
0
4
(0)
5
(0)
Diabetes
DAMAD
195
T
A990 + D225 vs A990
36m
161
157
10
11
-
-
2
1
12
12
0
1
-
(0)
-
(0)
Birmingham-A
192
T
T250 vs T100
2m
7
8
0
0
0
0
0
0
0
0
0
0
0
(0)
0
(0)
Birmingham-A
192
T
T500 vs T100
2m
5
8
0
0
0
0
0
0
0
0
0
0
0
(0)
0
(0)
Birmingham-A
192
T
T500 vs T250
2m
5
7
0
0
0
0
0
0
0
0
0
0
0
(0)
0
(0)
Miscellaneous
CAPRIE
277
T
C vs A325
24m
9599
9586
205
249
401
422
373
405
970
1063
187
166
92
(10)
98
(10)
ATTIS
278
P
TR vs ID
12m
535
529
3
2
3
2
8
8
14
12
0
0
-
(-)
-
(-)

Footnotes

APT1= antiplatelet regimen 1; APT2= antiplatelet regimen 2. "Non-fatal stroke" includes ischaemic and haemorrhagic strokes, together with strokes of unknown aetiology. "Vascular deaths" includes deaths that were known to have a vascular cause and deaths of unknown cause. Numbers of non-fatal major (extracranial) bleeds are shown first, with fatal bleeds in brackets. If separate information on fatal and non-fatal bleeds was not available then the total is shown in square brackets. '-':data unavailable

†Comparisons between different doses of antiplatelet drugs (other than aspirin) are not shown

I=individual participant data; T=tabular data checked with trialist; P=data extracted from publication(s)

A=aspirin; D=Dipyridamole; FIB = fibrinolytic therapy; TF = triflusal; R = ridogrel; SK = streptokinase; H = heparin; tPA = tissue plasminogen activator; IN = integrelin; S = sulfinpyrazone;TC = ticlopidine; ID = indobufen; E5510 = satigrel, GRB = GR3219B; L = lamifiban; 7E3 = abciximab; TI = tirofiban; PI = picotamide; TR = trapidil; ST = sulotroban; X = xemilofiban; CL = cilostazol; C = clopidogrel; doses in mg/day are shown for aspirin; dipyridamole and ticlopidine; antithrombotic or fibrinolytic drugs given as background treatment are shown in brackets

Average Duration means average scheduled treatment duration (with average duration of follow-up shown in brackets if different); m=months; d=days; h=hours

‡Aldusa-pilot regimen: In the 40 mg arm patients were to receive 120 mg on day 1 and 40 mg daily thereafter.